Genmab A/S (GMAB)
NASDAQ: GMAB · Real-Time Price · USD
20.59
+0.05 (0.24%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Genmab Revenue
In the year 2024, Genmab had annual revenue of 21.53B DKK with 30.67% growth. Genmab had revenue of 6.44B in the quarter ending December 31, 2024, with 35.34% growth.
Revenue (ttm)
21.53B DKK
Revenue Growth
+30.67%
P/S Ratio
4.28
Revenue / Employee
8,038,088 DKK
Employees
2,678
Market Cap
12.78B USD
Revenue Chart
* This company reports financials in DKK.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 21.53B | 5.05B | 30.67% |
| Dec 31, 2023 | 16.47B | 1.97B | 13.57% |
| Dec 31, 2022 | 14.51B | 6.09B | 72.33% |
| Dec 31, 2021 | 8.42B | -1.69B | -16.75% |
| Dec 31, 2020 | 10.11B | 4.75B | 88.43% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.90B |
GMAB News
- 3 days ago - Transactions in Connection with Share Buy-back Program - GlobeNewsWire
- 10 days ago - Genmab's Outlook Beyond Darzalex's Patent Cliff - Seeking Alpha
- 10 days ago - Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025 - GlobeNewsWire
- 15 days ago - Genmab A/S Share Capital Reduction - GlobeNewsWire
- 18 days ago - Transactions In Connection with Share Buy-back Program - GlobeNewsWire
- 24 days ago - Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons - GlobeNewsWire
- 25 days ago - TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer - GlobeNewsWire
- 25 days ago - Transactions in connection with share buy-back program - GlobeNewsWire